Asna Amin

Combined Clinical Trial Results of a HER2/<i>neu</i>(E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

George E. Peoples, Jarrod P. Holmes, Matthew T. Hueman et al. · Clinical Cancer Research · 2008 · 179 citations

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/<i>neu</i>Peptide (AE37) Vaccine

Jarrod P. Holmes, Linda C. Benavides, Jeremy D. Gates et al. · Journal of Clinical Oncology · 2008 · 136 citations

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

Ritesh Patil, Guy T. Clifton, Jarrod P. Holmes et al. · Journal of the American College of Surgeons · 2009 · 49 citations

Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study

Alexander Stojadinovic, Elizabeth A. Mittendorf, Jarrod P. Holmes et al. · Annals of Surgical Oncology · 2007 · 29 citations · Full text

Vaccination, Breast Oncology, Cancer Immunosurveillance +9

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Asna Amin, Linda C. Benavides, Jarrod P. Holmes et al. · Cancer Immunology Immunotherapy · 2008 · 26 citations · Full text

Vaccination, Clinical Recurrence, Tumor Immunology +11